




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61M 29/00	A1	(11) International Publication Number: WO 00/30710 (43) International Publication Date: 02 June 2000 (02.06.2000)
(21) International Application Number: PCT/US99/27577 (22) International Filing Date: 19 November 1999 (19.11.1999) (30) Priority Data: 09/196,797 20 November 1998 (20.11.1998) US (60) Parent Application or Grant PRECISION VASCULAR SYSTEMS, INC. [/]; (). JACOBSEN, Stephen, C. [/]; (). LIPPERT, John, A. [/]; (). WELLS, David [/]; (). DAVIS, Clark, C. [/]; (). BACKMAN, Kent [/]; (). MCKINNEY, David, R. ; ().	Published	
(54) Title: STENT APPARATUS AND METHOD (54) Titre: STENT COMPLET ET SA METHODE D'UTILISATION		
(57) Abstract <p>A stent (2) for disposition in a body passageway or duct to maintain the duct walls apart, for example, to allow the flow of fluid therethrough, includes an elongate flexible support wire (8) formed into an annular lattice having a central void, for disposition at a target location in the duct. Also included is an elongate flexible connecting wire (24) joined at a distal end to the annular lattice, and having a discontinuity for severing when supplied with a perturbation signal, a balloon catheter (30) having an expandable section (36a) disposable in the void of the annular lattice so that when the expandable section is expanded, it forces the annular lattice radially outwardly to contact, and hold apart the duct walls, and a fluid supply for supplying fluid to the expandable section (36a) of the balloon catheter (30) to cause it to expand. A perturbation signal source is provided for supplying the perturbation signal to the discontinuity of the connecting wire (24) to cause severance thereof.</p> (57) Abrégé <p>La présente invention concerne un stent (2) conçu pour être placé dans un passage ou un conduit du corps dont il maintient les parois écartées en vue, par exemple, du passage d'un fluide. Ce stent comprend un fil-support (8) formant un treillis annulaire autour d'une âme centrale creuse, qui doit être implanté en un emplacement-cible d'une lumière. L'ensemble comprend également: un fil de liaison souple (24) relié à une extrémité distale du treillis annulaire et présentant un point faible intégré en vue de sa rupture en cas de signal de perturbation; un cathéter à ballonnet (30) dont la partie extensible (36a) est destinée à être placée dans l'âme creuse du treillis annulaire de telle sorte qu'elle plaque, une fois gonflée, le treillis annulaire radialement contre les parois du conduit et maintienne les parois écartées, et une alimentation en liquide qui fournit du liquide à la partie extensible (36a) du cathéter à ballonnet (30) et la fait se dilater. Une source de signal permet d'envoyer un signal de perturbation à la zone affaiblie du fil de liaison (24) et provoque la coupure de ce fil.</p>		

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61M 29/00		(11) International Publication Number: WO 00/30710
A1		(43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/US99/27577		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 19 November 1999 (19.11.99)		
(30) Priority Data: 09/196,797 20 November 1998 (20.11.98) US		
(71) Applicant: PRECISION VASCULAR SYSTEMS, INC. [US/US]; 360 Wakara Way, Salt Lake City, UT 84108 (US).		
(72) Inventors: JACOBSEN, Stephen, C. ; 274 South 1200 East, Salt Lake City, UT 84102 (US). LIPPERT, John, A. ; 9006 North Jeremy Circle, Park City, UT 84098 (US). WELLS, David ; 3581 East Millstream Lane, Salt Lake City, UT 84109 (US). DAVIS, Clark, C. ; 4564 Wallace Lane, Salt Lake City, UT 84117 (US). BACKMAN, Kent ; 3299 Splendor Way, Salt Lake City, UT 84124 (US).		
(74) Agents: MCKINNEY, David, R. et al. ; Thorpe, North & Western, LLP, P.O. Box 1219, Sandy, UT 84091-1219 (US).		

Published*With international search report.*(54) Title: **STENT APPARATUS AND METHOD**

(57) Abstract

A stent (2) for disposition in a body passageway or duct to maintain the duct walls apart, for example, to allow the flow of fluid therethrough, includes an elongate flexible support wire (8) formed into an annular lattice having a central void, for disposition at a target location in the duct. Also included is an elongate flexible connecting wire (24) joined at a distal end to the annular lattice, and having a discontinuity for severing when supplied with a perturbation signal, a balloon catheter (30) having an expandable section (36a) disposable in the void of the annular lattice so that when the expandable section is expanded, it forces the annular lattice radially outwardly to contact, and hold apart the duct walls, and a fluid supply for supplying fluid to the expandable section (36a) of the balloon catheter (30) to cause it to expand. A perturbation signal source is provided for supplying the perturbation signal to the discontinuity of the connecting wire (24) to cause severance thereof.

FOR THE PURPOSES OF INFORMATION ONLY

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Description

5

10

15

20

25

30

35

40

45

50

55

5

STENT APPARATUS AND METHOD

10

BACKGROUND OF THE INVENTION

15

5 This invention relates to devices and methods for maintaining a blood vessel or like passageways in an open condition and, if desired, for delivering medication to the blood vessel or passageway walls.

20

10 Vascular medical treatment procedures are known to include, among other things, occluding a blood vessel by thrombogenic devices, and maintaining the blood vessels open by use of a stent. Stents typically used in the past have consisted of a stainless steel tube section which includes selectively positioned gaps or openings which enable the section to be expanded (with a typically shortening of the length), for example, by a balloon catheter, after the section is positioned at the desired location in the blood vessel.

25

30

15 Problems with the above prior art stent, among other things, are that the length changes when the tubular section is expanded (the length shortened), and the length of the stent is limited since the greater is the length, the more difficult it is to deliver the stent to a target location in the blood vessel. That is, the stent being rigid, does not navigate well in the blood vessel, especially around tight corners. Further, since the described stent cannot be very long, numerous stents must be used for a diffuse diseased blood vessel.

35

40

25 A stent design which alleviates some of the above problems is disclosed in U.S. Patent Nos. 5,292,331 and 5,674,278. This stent is comprised of a wire formed in a zig-zag pattern which extends in an annular configuration and which is compressed for disposition in a blood vessel and then expanded by a balloon catheter outwardly to hold the vessel walls apart.

45

50

35 A problem with the above and other unitary stents

55

5

-2-

10

is that in the course of delivering them to a desired location in a blood vessel, the stents may become separated from the carrier/placement device, typically a balloon catheter, and drift downstream in the blood vessel. This, of course, could give rise to a dangerous situation in which the stent became lodged at a branch, bend, or at a distal narrowing in the vessel, and thus inhibit the flow of blood. This may require surgical intervention to remove the errant stent.

15

5

20

10

Besides the vascular medical treatment of maintaining blood vessels in an open condition, there are numerous situations where application of medications to an affected area of a vessel wall may be beneficial, for example, in treating arterial sclerosis, aneurysms or other weakening of the vessel wall, occlusive lesions, etc. Application of such medications may be done systemically by injecting medication into the vessel and then allowing the blood to carry the medication to the affected area. The problem with this approach is that high dosages of medication are required to ensure that some small portion reaches the affected area, and the high dosage may be harmful to other organs or body parts.

25

15

30

20

35

Another approach to treating diseases of vessel walls is to place a block before and after the affected area and then inject medications into the portion of the vessel between the two blocks. The problem with this approach is that blood flow is stopped for a certain amount of time and this, in itself, is dangerous.

40

25

45

30

Still another prior art approach is to thread a catheter through the blood vessel to the affected area and then either supply the medication through the catheter to the affected area, or supply the medication through a needle which itself is threaded through the

50

55

5

-3-

10

catheter, pierce the vessel wall with the needle, and then supply the medication (see U.S. Patent No. 5,354,279). The problem with simply supplying the medication via the catheter is that much of the medication is carried away in the blood and may adversely affect other organs.

15

5

A further prior art approach to supplying medication to a vessel wall involves the use of an inflatable sleeve positioned adjacent the affected area, where the sleeve includes an annular cavity holding the medication. When the sleeve is inflated to expand outwardly, the medication held in the cavity is placed into contact with the vessel walls and released thereinto. The problem with this approach is that the blood vessel again is blocked for a time and thus a gradual therapeutic regimen is not possible.

20

10

25

15

The placement of the stent can itself be a source of disease, by irritating the vessel wall at the points of contact. Also, thrombus can form on the stent causing a potentially fatal situation. The ability to deliver or release drugs or anti-thrombotic agents could reduce these problems.

30

20

35

SUMMARY OF THE INVENTION

25

It is an object of the invention to provide a stent which is easily deployable in a vasculature or other passageway to maintain the passageway in an open condition.

40

30

It is also an object of the invention to provide such a stent which may be maintained under the control of the user, and not become separated from the deploying device, until so desired by the user.

45

It is a further object of the invention to provide such a stent capable of delivering medication,

50

55

5

-4-

10

therapeutic agents, and the like toward a blood vessel or other passageway wall.

5

15

It is still another object of the invention to provide such a stent which is non-occlusive and substantially non-inhibiting of blood flow or other fluids flowing in the passageway.

20

10

It is an additional object of the invention to provide such a stent which is capable of delivering medication substantially directly to a vessel or passageway wall.

25

15

The above and other objects are realized in an illustrative embodiment of a stent adapted for disposition in a blood vessel or other body passageway to maintain the passageway walls apart to allow the flow of blood or other fluids therethrough. This embodiment includes an elongate flexible support wire formed into an annular lattice having a central void, for disposition at a target location in the passageway, an elongate flexible connecting wire joined at a distal end to the annular lattice and having a discontinuity for severing when supplied with a perturbation signal, a balloon catheter having an expandable section disposable in the void of the annular lattice so that when the expandable section is expanded, it forces the annular lattice radially outwardly to contact and hold apart the passageway walls, a device for selectively expanding the expandable section of the balloon catheter, and a signal supply means for supplying a perturbation signal to the discontinuity of the connecting wire to cause severance thereof. With this structure, the stent may be delivered to the desired location and, since it is tethered by a connecting wire, control of the stent may be maintained until it is expanded at the target location to contact the

30

20

35

25

40

45

30

50

55

5

-5-

10

passageway walls. Then, the perturbation signal may be supplied to the discontinuity of the connecting wire so that the connecting wire is severed, after which the connecting wire may be removed from the passageway.

15

5 In accordance with another aspect of the invention, the support wire and connecting wire are tubular to enable carrying medication, and the support wire includes perforations through which medication may flow from the hollow of the support wire. In use, after the lattice has been expanded outwardly to contact the passageway walls, medication may be supplied through the hollow of the connecting wire to the hollow of the support wire, to then flow through the perforations to contact the passageway walls for treatment.

20

25

10 Advantagously, the perforations are positioned to cause the medication to flow generally outwardly from the lattice to thereby contact the passageway walls, but could be positioned to cause the medication to flow in any desired direction.

30

20

BRIEF DESCRIPTION OF THE DRAWINGS

35

The above and other objects, features and advantages of the invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:

40

FIG. 1 is a perspective, fragmented view of a detachable stent with drug delivery capabilities, in accordance with the principles of the present invention;

45

30 FIGS. 2A and 2B are perspective, fragmented views of the stent of FIG. 1, with a balloon catheter in place in the central void of the stent shown in the collapsed and expanded conditions respectively;

50

FIG. 3 is a perspective, fragmented view of an

55

5

-6-

10

alternative embodiment of a detachable, balloon expandable stent, in accordance with the present invention; and

15

FIGS. 4A-4C are cross sectional end views of blood vessels with stents showing various positions of perforations in the stents.

DETAILED DESCRIPTION

20

Referring to FIG. 1, there is shown a perspective, fragmented view of one embodiment of a stent 2 made in accordance with the present invention. The stent 2 includes three lattice sections 4a, 4b and 4c, stacked end to end as shown. Each lattice section is composed of an elongate, hollow flexible wire 8 formed into a generally gathered annular lattice having a central void 12. In this case, the wire 8 is formed generally of a zig-zag configuration circumferentially about the void 12, again as shown.

25

15

30

The three lattice sections 4a, 4b and 4c are joined together end to end by adhesive, welding, brazing or similar joining method. The locations at which the lattice sections are joined, such as joint 16, allow for communication between the hollows of the wires of the joined sections. This could be done by simply forming holes in each of the wires at the precise location of joining so that the hollows of each of the wires were in communication with one another through the holes. Alternatively, a continuous piece of tubing could be formed into a unitary stent, eliminating the need for joining the separate sections.

35

25

40

45

30

The hollow wires of the lattice sections 4a, 4b and 4c include a plurality of apertures 20 which face generally outwardly of the respective lattice and through which medication may flow from the hollow of the

50

55

5

-7-

respective wires thereout.

10

5 A hollow connecting wire 24 is coupled to the wire
of lattice 4a at a bend location 28 for example by
welding, brazing or an appropriate adhesive (or could be
15 formed of a single continuous hollow wire). The
coupling is made so that the hollow of the connecting
wire 24 joins or communicates with the hollow of the
wire of lattice 4a. Formed near or at the coupling
20 location is a discontinuity 32 to provide a breaking or
detachment point for detaching the lattice sections 4a,
4b and 4c from the connecting wire 24. The
discontinuity 32 could take a variety of forms including
25 a narrowing of the wire, a solder joint, a section of
weaker wire material, a section with selectively placed
cuts, a spot weld, or a section with chemically or
thermally changed properties, which when perturbed by a
perturbation signal, will cause the wire 24 to sever at
30 the discontinuity and allow separation of the lattice
sections 4a, 4b and 4c. The perturbation signal
advantageously is an ultrasonic signal transferred down
the wire 24 to cause mechanical separation at the
35 location of the discontinuity. See copending patent
application number 09/023,806 filed February 13, 1998,
for additional discussion of mechanisms for detaching
25 one portion of a wire from another portion, said
application being incorporated herein by reference.

40

Advantageously, the connecting wire 24 and the
wires from which the lattice sections 4a, 4b and 4c are
made, are constructed of stainless steel, platinum or
45 nickel-titanium alloy. The outside diameter of such
wire illustratively is .008 inches, with the inside
diameter being .004 inches.

50

Use of the stent of FIG. 1 may best be understood
by referring to FIG. 2A which shows a balloon catheter

55

55

5

-8-

10 36 disposed in the hollow 12 of the stent 2. The
balloon catheter 36 is of conventional design and
includes an expandable bladder or balloon 36a disposed
about a conventional guide wire 40. The balloon
15 5 catheter 36 also includes a catheter portion 36b
connected to a proximal end of the balloon 36a, to carry
saline, contrast or other fluid from a source 44 to
inflate the balloon 36a. The guide wire 40 extends not
only through the balloon portion 36a at the balloon
20 10 catheter 36 but also through the catheter portion 36b
and is used to guide the balloon catheter 36 with stent
2 in place over the balloon portion 36a, to a target
location. In particular, the guide wire 40 would be
25 inserted into a blood vessel (together with the
catheter) having a lesion or other vascular defect,
until the terminal end of the guide wire reached the
target site. The balloon catheter 36, with stent
30 positioned in place about the balloon portion 36a, would
then be placed over the guide wire 40 and moved to the
target site (or may be loaded onto the guide wire at
initial insertion). The balloon portion 36a of the
balloon catheter 36 would then inflated be by the
35 inflation source 44 to spread apart the stent 2 to
contact and spread apart the blood vessel walls at the
target site. The configuration of the lattice
25 sections 4a, 4b and 4c allow for the spreading apart of
the sections under pressure from the balloon section
36a, to contact and similarly spread apart the blood
vessel walls, as shown in FIG. 2B. Since the wires of
40 the lattice sections 4a, 4b and 4c are made of a
flexible but non-elastic material, such as stainless
steel, once the sections have been expanded as
45 30 illustrated in FIG. 2B, they will remain in the expanded
condition even after the balloon section 36a is

50

55

5

-9-

10

15

20

25

30

35

40

45

50

55

deflated. The next step in the treatment process is to deflate the balloon section 36a of the balloon catheter 36 and then remove the balloon catheter from the central void of the stent 2 and from the blood vessel in question. Next, medication from a medication source 48, such as syringe, is supplied via connecting wire 24 to the lattice sections 4a, 4b and 4c, to flow out through the apertures 20 and into contact with the expanded vessel walls (or into areas adjacent the stent, which will be discussed momentarily). Examples of medications which might be supplied and diseases which might be treated include Abciximals, gene therapy agents, Heparin, Urokinase, and antimytotics for treating clotting, restenosis and smooth muscle cell proliferation.

As an alternative to deflating the balloon catheter 36 and removing it from the void 12 of the stent 2 before supplying the medication, would be to leave the expanded balloon portion 36a in place while supplying the medication to the lattice sections 4a, 4b and 4c. Also, a perfusion balloon could be used in this circumstance to provide for longer therapies.

After medication has been supplied to the stent 2 and ultimately the vessel walls or the therapy is otherwise complete, the stent is detached from the connecting wire 24 by applying a perturbation signal from a signal source 52, as described in the afore-cited patent application. After detachment, the connecting wire 24 and guide wire 40 are removed from the blood vessel, leaving the stent 2 in place in the vessel in the expanded condition, to maintain the vessel walls apart.

Although the stent of FIGS. 1 and 2 had been described for serving both as a stent to hold vessel

5

-10-

walls apart and as a drug delivery device, the stent could simply be used to hold the vessel walls apart without the attendant drug or medication delivery, in which case the stent need not be hollow. The advantage of placing the stent and expanding it before detachment of the connecting wire 24 is that the stent is much less likely to be inadvertently separated from the balloon portion 36a of the balloon catheter 36 during insertion and expansion or enlargement of the stent. Of course, stents which do become separated could migrate in the blood vessel to a location where the stent could either clog the flow of blood in the blood vessel or otherwise damage the blood vessel or other body organs.

FIG. 3 is a perspective view of another embodiment of the present invention. In this embodiment, a tubular connecting wire 64 is joined through a discontinuity 68 to a proximal end of a tubular coil lattice 72. The lattice 72 is constructed of a hollow wire 76, formed in a first helical turn 72a which then bends to extend in the opposite direction in a second helical turn 72b which then, again, bends to extend in the same direction as the first helical turn to form a third helical turn 72c, etc. Openings 80 are formed on the outside of the wire 76 (or other locations as will be discussed) forming the lattice to allow delivery of medication to vessel walls of the vessel in which the lattice 72 is deployed, as discussed earlier for the embodiment of FIGS. 1 and 2. A balloon catheter would be used, as also discussed earlier to expand the helix 72 after positioning of the target site, medication would then be supplied to treat the target vessel walls, etc.

FIGS. 4A, 4B and 4C show a fragmented, cross-sectional view of a vessel wall 84 with a hollow wire 88a, 88b and 88c respectively, having openings or

55

5

-11-

10

perforations positioned in different locations. In FIG. 4A, the openings 90 positioned on the outside, directly against the vessel wall; in FIG. 4B, the openings 92 are positioned toward the outside but not directly against the vessel wall; and FIG. 4C, the openings 94 are positioned toward the inside of the wire (which would allow for more gradual, less concentrated drug delivery therapy for the vessel wall).

5

15

20

10

It is to be understood that the above-described arrangements are only illustrative of the principles of the present invention. Numerous modifications and alternative arrangements may be devised by those skilled in the art without departing from the spirit and scope of the present invention and the appended claims are intended to cover such modifications and arrangements.

25

15

30

35

40

45

50

55

Claims

5

10

15

20

25

30

35

40

45

50

55

5

-12-

CLAIMS

10

What is claimed is:

1. A stent for disposition in a body passageway to allow delivery of a solution to the passageway walls, said stent comprising

15

an elongate, hollow flexible wire, a distal end of which is formed into a generally gathered annular lattice with a central void, extending from a dispatch location of the wire, for disposition at a target location in the passageway, said lattice including perforations through which solution may flow from the hollow of the wire, said wire further including a discontinuity located generally at or near the dispatch location,

20

10

25

15

means for mechanically stimulating the wire to cause detachment of the lattice at the discontinuity,

30

20

an expandable balloon disposed in the void of the lattice which, when expanded, forces the lattice outwardly to contact the passageway walls at the target location, and

35

means for selectively expanding and contracting the balloon.

25

2. A stent as in Claim 1 wherein the wire is made of stainless steel.

40

3. A stent as in Claim 2 wherein the outside diameter of the wire is about 0.008 inches or less.

45

30

4. A stent as in Claim 1 wherein said lattice is formed generally of a zig-zag configuration circumferentially about the void.

50

5. A stent as in Claim 1 wherein said lattice is

55

5

-13-

10

formed generally of a coil configuration circumferentially about the void.

15

6. A stent as in Claim 5 wherein said coil configuration comprises a length of wire alternately coiled about the void, approximately one turn in a first direction and then approximately another turn in the opposite direction, etc.

20

7. A stent as in Claim 1 further including means attachable to a proximal end of the wire for supplying a solution to the hollow of the wire for transport to and out the perforation in the lattice.

25

8. A stent as in Claim 1 wherein said perforations are formed in the wire to generally face the passageway walls.

30

9. A stent as in Claim 1 wherein said perforations are formed in the wire to generally face inwardly of the passageway walls.

35

10. A stent for disposition in a duct to maintain the duct walls apart to allow the flow of fluid therethrough, said stent comprising

40

an elongate flexible support wire formed into an annular lattice having a central void, for disposition at a target location in the duct,

45

an elongate flexible connecting wire joined at a distal end to the annular lattice and having a discontinuity for severing when supplied with a mechanical perturbation signal,

50

a balloon catheter having an expandable section disposable in the void of the annular lattice so that

55

5

-14-

10

when the expandable section is expanded, it forces the annular lattice radially outwardly to contact and hold apart the duct walls,

5

means for selectively expanding the expandable section of the balloon catheter, and

15

means for supplying a mechanical perturbation signal to the discontinuity of the connecting wire to cause severance thereof.

20

11. A stent as in Claim 10 wherein the discontinuity comprises a narrowed portion of the wire, and wherein the perturbation signal supplying means comprises an ultrasonic signal generator.

25

12. A stent as in Claim 10 wherein the discontinuity comprises a portion of the wire made from a material different from the material of the rest of the wire, and wherein the perturbation signal supplying means comprises an ultrasonic signal generator.

30

20

13. A stent as in Claim 10 wherein the discontinuity comprises one or more cuts in the wire, and wherein the perturbation signal supplying means comprises an ultrasonic signal generator.

35

25

14. A stent as in Claim 10 wherein the discontinuity comprises a spot weld, and wherein the perturbation signal supplying means comprises an ultrasonic signal generator.

40

30

15. A stent as in Claim 10 wherein the support wire and connecting wire are tubular having central hollows which are in communication, wherein the lattice includes a plurality of openings through which

45

50

55

5

-15-

10

medication may flow from the hollow of the support wire forming the lattice, said stent further including means for selectively supplying medication to the hollow of the connecting wire to flow to the hollow of the support wire and out the openings.

5

15

16. A stent as in Claim 15 wherein the openings are positioned to face generally outwardly of the lattice.

20

10

17. A stent as in Claim 10 wherein the wires are made of a material selected from the group consisting of stainless steel, platinum, platinum alloys and nickel-titanium alloy.

25

15

18. A method of holding open a section of a body duct vessel comprising the steps of:

30

20

(a) inserting a balloon catheter at an insertion point in the body duct and therethrough until the balloon portion of the catheter is located in said section of the body duct,

35

25

(b) providing a tubular expandable stent having a central void, with the balloon portion of the catheter disposed in the void, the stent further having a connecting wire joined to the stent and itself having a discontinuity which severs upon receipt of a mechanical perturbation signal, said connecting wire extending from the stent back through the body duct and therefrom at the insertion point,

40

30

(c) inflating the balloon portion of the catheter to expand the tubular stent outwardly to contact and hold apart the walls of the section of the body duct,

45

(d) deflating the balloon portion of the catheter and removing the catheter from the body duct,

50

55

5

-16-

10

(e) supplying a mechanical perturbation signal to the connecting wire to sever the wire, and removing the severed wire from the body duct.

15

5 19. A method as in Claim 18 wherein the stent is formed from a hollow wire, wherein the connecting wire is hollow and in communication with the hollow of the stent wire, and wherein the stent wire includes openings to allow medication introduced into the hollow thereof to flow thereout, said step (c) further comprising the step of:

20

10

(f) supplying medication to the hollow of the connecting wire to flow to the hollow of the stent wire and then therefrom through the openings in the stent wire.

25

15

30

20

20. A method as in Claim 19 wherein the openings in the stent wire are located to direct medication outwardly of the stent, and wherein step (f) includes ejecting medication through the openings in the stent wire toward the walls of the section of the body duct.

35

25

21. A method as in Claim 19 wherein the openings in the stent wire are located to direct medication inwardly of the stent, and wherein step (f) includes ejecting medication through the openings in the stent wire.

40

45

30

22. A method as in Claim 19 wherein step (f) comprises supplying medication in pulses to the hollow of the connecting wire.

50

23. A method as in Claim 18 wherein the stent is formed from a hollow wire, wherein the connecting wire

55

5

-17-

10

is hollow and in communication with the hollow of the stent wire, and wherein the stent wire includes openings to allow medication introduced into the hollow thereof to flow out of the hollow of the stent wire, said step

5 (d) further comprising the step of:

15

(g) supplying medication to the hollow of the connecting wire to flow to the hollow of the stent wire and then therefrom through the openings in the stent wire.

20

10

24. A method as in claim 23 wherein the openings in the stent wire are located to direct medication outwardly of the stent, and wherein step (g) includes ejecting medication through the openings in the stent wire toward the walls of the section of the blood vessel.

25

15

30

20

25. A method as in Claim 23 wherein step (g) comprises supplying medication in pulses to the hollow of the connecting wire.

35

25

26. A method as in Claim 18 wherein the stent is formed of a wire shaped in a zig-zag pattern circumferentially about the central void.

40

27. A method as in Claim 18 wherein the stent is formed of a coil wire coiled about the central void.

45

30

28. A method as in Claim 27 wherein the coil wire extends circumferentially about the central void in a first direction, then curves to extend circumferentially in a second direction opposite the first direction, and then curves to extend again in the first direction, etc. for a plurality of extensions and curves.

50

55

5

-18-

10

29. A stent system for disposition in a body duct to maintain the duct walls apart, said stent system comprising:

5 a generally tubular-shaped stent for disposition at a target location in the duct,

15

an elongate flexible connecting wire joined at a distal end to the stent for preventing unwanted migration of the stent, said wire including a discontinuity for severing when supplied with a mechanical perturbation signal, and

20

10

means for supplying a mechanical perturbation signal to the discontinuity of the connecting wire to cause severance thereof.

25

15

30. A stent system as in Claim 29 further including

30

means for selectively expanding the stent radially outwardly to contact and hold apart the duct walls.

20

31. A stent system as in Claim 29 wherein the stent comprises an elongate flexible support wire formed into an annular lattice.

35

25

32. A stent system as in Claim 29 wherein the support wire and connecting wire are tubular having central hollows which are in communication, wherein the lattice includes a plurality of openings through which the medication may flow from the hollow of the support wire forming the lattice, said stent system further including means for selectively supplying medication to the hollow of the connecting wire to flow to the hollow of the support wire and out the openings.

40

45

50

55




Fig. 1




Fig. 2B




Fig. 2A




Fig. 4A




Fig. 4B




Fig. 4C




Fig. 3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/27577

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61M 29/00
US CL : 606/108, 191, 195, 198

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 606/108, 191, 195, 198

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US 5,882,335 A (LEONE et al.) 16 March 1999, entire document. <i>4000. 1000 1000 1000 1000</i>	1-32

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

09 FEBRUARY 2000

Date of mailing of the international search report

24 FEB 2000

Name and mailing address of the ISA-US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KEVIN TRUONG

Telephone No. (703) 308-3767

THIS PAGE BLANK (USPTO,